Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

LentiGlobin

Regeneron and Bluebird sign $100m cell therapies deal

Six targets chosen from TCR and other cell therapy platforms

- PMLiVE

Bluebird’s first gene therapy gets European fast track

For once, Europe set for approval and launch ahead of US

- PMLiVE

Daily Brief: Brexit reshuffle brings new health minister, Celgene thalassemia success, Wellcome ready to leap into future

A round-up from pharma, biotech and healthcare

- PMLiVE

More impressive data from Bluebird’s gene therapy in thalassemia and sickle cell disease

Cell and gene therapy specialist Bluebird going head-to-head with partner Celgene

- PMLiVE

bluebird bags breakthrough status for CALD gene therapy

News comes after impressive data from a phase II/III trial

Celgene building

Celgene boosts CAR-T stake again with Bluebird Bio deal

The US biotech could receive $70m in development milestones for the candidate

Actelion HQ Switzerland

Actelion gets EU go-ahead for Uptravi in PAH

Oral therapy predicted to become $1bn-plus product

- PMLiVE

Mixed news for gene therapies at ASH conference

GSK unveils successful trial, but there was disappointing news for Bluebird

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links